Glenmede Trust’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

Glenmede Trust’s Portfolio OSIR Stock Details OSIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-71	Closed	–	–	2906
2016 Q1	$0	Hold	71	–	–	﹤0.01%	2864
2015 Q4	$0	Hold	71	–	–	﹤0.01%	2943
2015 Q3	$1K	Buy	+71	New	+$1.37K	﹤0.01%	2675
2015 Q2	–	Sell	-4,500	Closed	-$79K	–	2932
2015 Q1	$79K	Hold	4,500	–	–	﹤0.01%	1535
2014 Q4	$71K	Hold	4,500	–	–	﹤0.01%	1649
2014 Q3	$56K	Hold	4,500	–	–	﹤0.01%	1657
2014 Q2	$70K	Sell	4,500 -400	-8%	-$5.88K	﹤0.01%	1539
2014 Q1	$64K	Hold	4,900	–	–	﹤0.01%	1575
2013 Q4	$78K	Sell	4,900 -500	-9%	-$7.97K	﹤0.01%	1495
2013 Q3	$89K	Hold	5,400	–	–	﹤0.01%	1423
2013 Q2	$54K	Buy	+5,400	New	+$56.7K	﹤0.01%	1505

Other funds holding OSIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

QS Investors New York $8.47B AUM 30.71% 1-Year Est. Return

Glenmede Trust's OSIR Position: Q2 2016 in Review

Glenmede Trust sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q2 2016, closing a stake of 71 shares.

Glenmede Trust first reported a position in OSIR in Q2 2013 and held it in 11 quarters. The position peaked at $89K in Q3 2013. 68 funds tracked by Wall St. Rank hold OSIR as of Q2 2016.

Glenmede Trust reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
Glenmede Trust sold 71 Osiris Therapeutics, Inc. Common Stock shares in Q2 2016.
Glenmede Trust first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and held it in 11 quarters.
Glenmede Trust's Osiris Therapeutics, Inc. Common Stock position peaked at $89K in Q3 2013.
68 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q2 2016.

Based on Glenmede Trust's 13F filing for Q2 2016, filed 5 Aug 2016.